Drug screening joins gene discovery in the zebrafish tank, as researchers seek drugs that could prevent melanoma development.
Melanoma tumors are composed of transformed melanocytes, which derive from the embryonic neural crest. Investigators used a zebrafish model to explore how processes that regulate neural crest development interact with mutations in the BRAF oncogene, the most commonly mutated gene in human melanoma.
The researchers discovered a gene expression pattern linking neural crest precursor cells to mature melanoma cells in transgenic BRAF(V600E), p53-null zebrafish embryos. The neural crest progenitors from these embryos failed to terminally differentiate. The similar gene expression pattern suggested that melanoma cells have “de-differentiated” to an earlier stage of embryonic development.
The authors then set out to identify compounds that would sup…
Reviewing Author
DisclosuresConsultant / advisory board Lubax; WorldCare Clinical
EquityLubax
Grant / Research support NIH; Department of Defense; American Skin Association; Piramal
Editorial boardsBritish Journal of Dermatology; Journal of the American Academy of Dermatology; Journal of Investigative Dermatology
Leadership positions in professional societies American Academy of Dermatology (Chair, Skin Cancer and Melanoma Committee); American Board of Dermatology (Director)
DisclosuresConsultant / advisory board Lubax; WorldCare Clinical
EquityLubax
Grant / Research support NIH; Department of Defense; American Skin Association; Piramal
Editorial boardsBritish Journal of Dermatology; Journal of the American Academy of Dermatology; Journal of Investigative Dermatology
Leadership positions in professional societies American Academy of Dermatology (Chair, Skin Cancer and Melanoma Committee); American Board of Dermatology (Director)